StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Organon — Zetia (ezetimibe) International sales by Year

Organon — Zetia (ezetimibe) International sales ($M) ($M)

QuarterlyAnnual

Merck Organon — Zetia (ezetimibe) International sales: $337,000,000M in FY2025, up 8.7% from a year earlier.

Latest, FY2025
337,000,000
Period ended Dec 31, 2025
Change on a year earlier
+8.7%
310,000,000 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below

Where the FY2025 figure comes from

Source: Organon & Co. SEC Filing (0001628280-26-011125) ↗

Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon — Zetia (ezetimibe) International sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025337,000,000+8.7%Organon & Co. SEC Filing (0001628280-26-011125) ↗
FY2024Dec 31, 2024310,000,000-1.3%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2023Dec 31, 2023314,000,000-13.5%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2022Dec 31, 2022363,000,000-1.4%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2021Dec 31, 2021368,000,000-23.8%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2020Dec 31, 2020483,000,000-16.0%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2019Dec 31, 2019575,000,000–Organon & Co. SEC Filing (0001821825-22-000002) ↗

Cite this data

StockData. (2026). Merck Organon — Zetia (ezetimibe) International sales ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-zetia-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.